Telix Pharmaceuticals Limited (ASX: TLX) (NASDAQ: TLX) has confirmed it will release full-year results for the period ended 31 December 2025 on 20 February 2026. The Melbourne-based biopharmaceutical Company announced the timing through an ASX release on 4 February 2026. An investor webcast and conference call will be held at 9:30 a.m. AEDT on the same day.
Figure 1: Telix Pharmaceuticals corporate logo highlighting the Company’s global biopharmaceutical brand [Telix Pharmaceuticals]
The results announcement comes during a period of board transition for Telix Pharmaceuticals. Ms Tiffany Olson resigned as Non-Executive Director and Board Chair effective 3 February 2026. Dr Mark Nelson, a long-standing independent Non-Executive Director since the Company’s ASX listing, has been appointed as Interim Chair.
When Will The Telix Pharmaceuticals Investor Webcast Take Place?
Telix Pharmaceuticals investor webcast will be held at 9:30 a.m. AEDT on Friday 20 February 2026. For United States participants, this translates to 5:30 p.m. EST on Thursday, 19 February 2026. Participants can register through the provided link to join the webcast.
The full year results for the period ended 31 December 2025 will be released on Friday, 20 February 2026 AEDT. This corresponds to Thursday, 19 February 2026 EST for United States markets. The timing allows both Australian and United States investors to access the results simultaneously.
What Board Changes Have Occurred At Telix Pharmaceuticals?
Telix Pharmaceuticals shares faced a leadership transition as Ms Tiffany Olson resigned from her positions. She stepped down as Non-Executive Director and Board Chair effective 3 February 2026. Ms Olson had served on the Board since March 2022.
Dr Mark Nelson has taken over as Interim Chair following Ms Olson’s departure. Dr Nelson has been an independent Non-Executive Director since Telix’s listing on the Australian Securities Exchange. The Board is in advanced stages of a process to appoint new Non-Executive Directors.
Figure 2: Tiffany Olson, former Non-Executive Director and Board Chair of Telix Pharmaceuticals [Telix Pharmaceuticals]
The Company is committed to appointing a new Independent Chair as soon as feasible. Dr Nelson stated the Board supports Ms Olson’s personal decision. He extended sincere thanks for her service and significant contribution throughout an important phase in the Company’s evolution.
How Will The Leadership Change Impact Telix Operations?
Dr Nelson, Interim Chair of Telix, assured investors that the transition will not impact near-term milestones. The Company’s long-term growth strategy remains unchanged. Telix Pharmaceuticals has an exceptionally strong commercial business and pipeline.
Figure 3: Dr Mark Nelson, Interim Chair and independent Non-Executive Director of Telix Pharmaceuticals [Telix Pharmaceuticals]
The Board expects 2026 to be a pivotal year for Telix Pharmaceuticals. The leadership transition is designed to be orderly. The Board is committed to working together to ensure continuity during this period.
Telix Pharmaceuticals ASX listing provides transparency for Australian investors during the transition. The Company also maintains a listing on the Nasdaq Global Select Market. This dual listing structure supports investor confidence across both markets.
What Does Telix Pharmaceuticals Do?
Telix Pharmaceuticals is a biopharmaceutical company focused on therapeutic and diagnostic radiopharmaceuticals. The Company also develops associated medical technologies. Telix is headquartered in Melbourne, Australia.
International operations span the United States, the United Kingdom, Brazil, Canada, Europe and Japan. European operations are based in Belgium and Switzerland. Telix is developing a portfolio of clinical and commercial-stage products.
The Company aims to address significant unmet medical needs in oncology and rare diseases. Telix Pharmaceuticals shares are listed on the ASX and the Nasdaq Global Select Market. This dual listing provides access to both the Australian and the United States capital markets.
Telix Pharmaceuticals Shares Trading Performance
Telix Pharmaceuticals ASX shares last traded at $9.995 per share. The Company has a market capitalisation of $3.45 billion. The stock has traded in a 52-week range of $9.880 to $31.970 per share.
Figure 4: One-year share price performance of Telix Pharmaceuticals Limited (ASX: TLX) [ASX]
Final Thoughts
The upcoming Telix Pharmaceuticals investor webcast on 20 February 2026 will provide clarity on FY25 performance. The board transition to Dr Mark Nelson as Interim Chair is not expected to disrupt operations. Investors will focus on commercial performance and pipeline progress when results are released.
Telix Pharmaceuticals shares remain under investor scrutiny as the Company navigates leadership changes. The appointment of a new Independent Chair will be watched closely. The FY25 results will offer insight into the Company’s commercial trajectory and strategic priorities for 2026.
Also Read: Worley Wins Reimbursable EPC Contract for Phase 2 of CP2 Project
FAQs
Q1. When will Telix Pharmaceuticals release FY25 results?
Ans. Telix will release full-year results for the period ended 31 December 2025 on Friday, 20 February 2026 AEDT.
Q2. Who is the new Interim Chair of Telix Pharmaceuticals?
Ans. Dr Mark Nelson, a long-standing independent Non-Executive Director, has been appointed as Interim Chair effective 3 February 2026.
Q3. What time is the Telix investor webcast?
Ans. The investor webcast will be held at 9:30 a.m. AEDT on Friday 20 February 2026, which is 5:30 p.m. EST on Thursday 19 February 2026.
Q4. Why did Tiffany Olson resign from Telix?
Ans. Ms Tiffany Olson resigned as Non-Executive Director and Board Chair effective 3 February 2026 for personal reasons.
